Trulieve Cannabis Corp. closed its third quarter with $230 million in revenue and a 64% gross margin, numbers that would stand out in any retail segment but carry extra weight for a cannabis operator still digesting a federal rule change. The Tallahassee-based company, now trading on the NYSE under TRLV, reported the results for the period ended September 30, 2026, alongside a disclosure that may matter more than the quarterly print itself: final DEA registrations tied to the rescheduling of state-licensed medical marijuana to Schedule III.
Why the Schedule III Shift Changes the Math
For years, multi-state operators have absorbed the bite of Section 280E, the tax code provision that bars businesses trafficking in federally controlled Schedule I or II substances from deducting ordinary business expenses. Move medical marijuana to Schedule III, and that constraint loosens considerably. Trulieve's management pointed directly to this, crediting rescheduling with unlocking DEA registration, removal of the 280E burden, and the NYSE uplisting in the same breath. That's not a small cluster of events. A lighter tax posture flows straight to free cash flow, and free cash flow is exactly what funds store buildouts, cultivation expansions, and debt paydown without tapping capital markets.
Cash Generation Over Growth-at-Any-Cost
The company generated $74 million in cash flow from operations and $45 million in free cash flow during the quarter, bringing nine-month totals to $183 million and $120 million respectively. In practice, that kind of cash discipline matters more to lenders and institutional holders than a flashy revenue headline. Trulieve used part of that balance sheet strength to retire a $65 million mortgage note tied to its Jefferson County, Florida cultivation site ahead of its 2028 maturity - a straightforward move to cut interest expense, but also a signal that management is prioritizing leverage reduction over aggressive expansion financed by debt.
Store Footprint, Product Licensing, and a New Georgia Signal
Retail sales drove 95% of revenue, underscoring just how central the dispensary network remains to Trulieve's model despite its cultivation and processing scale - 3.5 million square feet across its footprint, feeding 208 retail locations. Two new stores opened in Marco Island, Florida, and Dunwoody, Georgia, modest additions on their own, but Georgia is where the more interesting operational story sits. The company reported a seven-fold jump in traffic there following the state's medical program expansion on July 1, paired with new product lines under the Modern Flower and Roll One names. A seven-fold traffic increase from a low base is not the same as sustained demand at scale, and operators watching Georgia's rollout should treat early figures as a signal worth monitoring rather than a settled trend.
On the brand side, Trulieve closed a royalty-free license for Alien Labs and Connected products covering Florida and Texas, with a right of first refusal on additional markets. Licensing deals like this let a vertically integrated operator diversify its wholesale menu and SKU mix without the overhead of building a brand from scratch - a common play in mature cannabis markets where shelf differentiation increasingly separates winning dispensary chains from the rest.
What Operators and Investors Should Watch Next
Corporate domestication to Delaware, inclusion in the S&P Total Market Index and S&P Completion Index, and the NYSE listing itself all point toward a company positioning for broader institutional ownership - something harder to attract under the compliance ambiguity that has long shadowed cannabis equities. None of this changes the underlying retail fundamentals, though: dispensary operators still answer to state seed-to-sale tracking requirements, local zoning limits, and strict marketing and age-verification rules regardless of federal tax treatment. Rescheduling eases a tax burden; it does not touch the patchwork of state licensing, lab testing, and packaging compliance that still governs how medical cannabis reaches a counter.